Back to search results

TOGETHER AMPLIFY-PsO Study: Tirzepatide for Psoriasis and Obesity

This study is looking at how well adding a medication called tirzepatide (LY3298176) works for people who are already taking ixekizumab (LY2439821) for moderate-to-severe plaque psoriasis (PsO). Participants must also be overweight or have obesity. The main goals are to see if tirzepatide helps improve your quality of life related to skin issues and if it helps with weight loss. We are looking for about 200 participants aged 18 and older. The study is currently unclear on its recruitment status.

Study design
This is an interventional study planning to enroll 200 participants. It will investigate the effects of tirzepatide.
What's involved
The study will last up to 12 months. Participants will receive tirzepatide administered subcutaneously (SC).
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints, including quality of life and weight reduction, will be measured at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06857942

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Recruiting
PHASE4Ages 18+InterventionalTreatment
Eli Lilly and Company
~200 participants
Updated 2026-06-03 on ClinicalTrials.gov
What's tested:Tirzepatide

At a glance

Recruiting sites
40 of 40 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1)
Measured over 12 months
+1 more outcome measured

Conditions

Psoriasis
Overweight or Obesity

Explore related trials

ObesityOverweightPsoriasis

Where it's being run

40 sites across 22 states
Texas6
Florida5
California4
Michigan3
Indiana2
New Jersey2
North Carolina2
Washington2

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant)
Have body mass index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m² to \<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases).
Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide.
Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).

Exclusion

Have currently received ixekizumab for more than 4 months or less than 2 months.
Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.
Are currently enrolled in any other clinical study.
Have a known hypersensitivity to tirzepatide or to any of its component.
Have a personal or family history of medullary thyroid cancer.
Have multiple endocrine neoplasia type 2.
Have type I diabetes mellitus.
Have a history of chronic or acute pancreatitis at any time before screening (Visit 1).
Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.
Have a history of ketoacidosis or hyperosmolar state/coma.
Have a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening.
Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/constipation/vomiting.

What this trial measures

  • Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1)12 months

    The DLQI is a simple, patient-reported, 10-item, validated, quality of life questionnaire. Scores range from 0 to 30, with higher scores indicating greater impairment of quality of life.

  • Percentage of Participants Achieving at least 10% Weight Reduction12 months

    Percentage of participants achieving at least 10% weight reduction.